Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a clinical trial, phase ii.

Results The trial accrued a total of 32 patients.

Who Took Part

The abstract describes 32 patients taking part.

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, men only.

How the Study Was Run

The researchers set it up as an open-label study.

Everyone knew when Vasopressin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Bleeding was graded using a score based on the Chutkan scale and tumor perfusion was evaluated by dynamic contrast-enhanced magnetic resonance imaging.

What Was Measured

PubMed files the paper under topics including Deamino Arginine Vasopressin, Hemorrhage, Hemostatics and Rectal Neoplasms.

The authors tagged it with the keywords Drug repurposing, Gastrointestinal cancer, Hemostasis, Tumor perfusion, Vasopressin peptide analog and von Willebrand factor.

What This Means in Plain Language

The paper is an open-label study of Vasopressin and Desmopressin in 32 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2020 (Investigational new drugs), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.